{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T06:45:03Z","timestamp":1696315503545},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,1,15]],"date-time":"2015-01-15T00:00:00Z","timestamp":1421280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2015,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Patients with acute lymphoblastic leukaemia (<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>) after cytotoxic chemotherapy or haematopoietic stem cell transplantation (<jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content>) are at risk for life\u2010threatening invasive fungal disease (<jats:styled-content style=\"fixed-case\">IFD<\/jats:styled-content>). The aim was to evaluate the characteristics, antifungal therapy and outcome of adult patients with <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> after chemotherapy or <jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content> receiving caspofungin empirically in a clinical setting. Retrospective chart reviews were conducted at nine large tertiary care centres in Germany. Adult patients with <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> treated empirically with caspofungin according to the product label between 2006 and 2012 were eligible. Data were extracted as case reports. In total, 25 patients (12 males, 13 females; median age 37\u00a0years; 19 with B\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>, 6 with T\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>) with 28 treatment episodes because of suspected <jats:styled-content style=\"fixed-case\">IFD<\/jats:styled-content> (18 episodes after chemotherapy, 10 episodes after allogeneic <jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content>) were included in the analysis. Empirical caspofungin therapy (median duration: 19\u00a0days, range 1\u2013105\u00a0days) was given as first\u2010line monotherapy in 20 (71.4%), second\u2010line monotherapy in five (17.9%) and combination therapy in three (10.7%) episodes respectively. Therapy rated successful according to the physician's overall assessment (inflammatory parameters, clinical symptoms): 20 (95%) of 21 evaluable episodes with therapy duration of at least 8\u00a0days. Empirical caspofungin appears to be an effective therapeutic option in critically ill adult <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> patients with suspected <jats:styled-content style=\"fixed-case\">IFD<\/jats:styled-content> in clinical practice.<\/jats:p>","DOI":"10.1111\/myc.12277","type":"journal-article","created":{"date-parts":[[2015,1,15]],"date-time":"2015-01-15T18:01:50Z","timestamp":1421344910000},"page":"76-81","source":"Crossref","is-referenced-by-count":0,"title":["Empirical caspofungin therapy in clinical practice for suspected invasive fungal disease in adults with acute lymphoblastic leukaemia"],"prefix":"10.1111","volume":"58","author":[{"given":"Michael G.","family":"Kiehl","sequence":"first","affiliation":[{"name":"Medical Department I Frankfurt\/Oder General Hospital Frankfurt (Oder) Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerlinde","family":"Egerer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V University Hospital Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[{"name":"Department of Medicine I: Hematology Oncology, and Stem\u2010Cell Transplantation, University Medical Center Freiburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Gross","sequence":"additional","affiliation":[{"name":"Department of Medicine I: Hematology Oncology, and Stem\u2010Cell Transplantation, University Medical Center Freiburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,1,15]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.175"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/13693780701218689"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62187-4"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2008.09.003"},{"key":"e_1_2_7_6_1","first-page":"373","volume-title":"The EBMT Handbook: Haematopoietic Stem Cell Transplantation","author":"G\u00f6kbuget N","year":"2008"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2011.02158.x"},{"key":"e_1_2_7_8_1","unstructured":"G\u00f6kbugetN HauswirthAW KnebaM SchanzU OttmannO.Akute Lymphatische Leuk\u00e4mie. Leitlinie. Stand Februar [WWW document] 2012. URLhttp:\/\/www.dgho-onkopedia.de\/de\/onkopedia\/leitlinien\/akute-lymphatische-leukaemie[accessed 1 April 2014]."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1086\/517849"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.740561"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1086\/597395"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2011.01.011"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1867-1"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr271"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05134-11"},{"key":"e_1_2_7_16_1","first-page":"267","article-title":"Caspofungin for prophylaxis and treatment of fungal infections in adolescents and adults: a meta\u2010analysis of randomized controlled trials","volume":"67","author":"Yuan X","year":"2012","journal-title":"Pharmazie"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3278"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00425-10"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2008.01572.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1086\/588660"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040446"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/13693786.2012.693213"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01128-10"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000313993"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-379016"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fmyc.12277","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.12277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T03:58:47Z","timestamp":1696219127000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/myc.12277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,15]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1111\/myc.12277"],"URL":"https:\/\/doi.org\/10.1111\/myc.12277","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,15]]}}}